Edition:
United Kingdom

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

86.00DKK
3:59pm GMT
Change (% chg)

kr.-1.00 (-1.15%)
Prev Close
kr.87.00
Open
kr.87.00
Day's High
kr.87.00
Day's Low
kr.85.00
Volume
72,300
Avg. Vol
119,803
52-wk High
kr.141.00
52-wk Low
kr.82.00

Select another date:

Thu, Dec 7 2017

BRIEF-Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon

* ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

* ‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​

BRIEF-Zealand reports royalty revenue Of DKK 10.3 mln for Q3

* REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017

BRIEF-Zealand Pharma granted orphan drug designation by FDA

* REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME

New Zealand forestry a first test in nationalist party's protectionist agenda

WELLINGTON Some New Zealand forest owners are suspending replanting of trees and re-thinking investments as the country's third-largest export earner finds itself in the sights of maverick politician Winston Peters' protectionist agenda.

BRIEF-Zealand Pharma to cooperate with Torrey Pines Institute for Molecular Studies

* REG-ZEALAND PHARMA AND TORREY PINES INSTITUTE FOR MOLECULAR STUDIES ANNOUNCE RESEARCH COLLABORATION

BRIEF-Zealand Pharma and Orbit Discovery enter into research collaboration

* REG-ZEALAND AND ORBIT DISCOVERY ENTER INTO RESEARCH COLLABORATION

BRIEF-Zealand Pharma to present at Morgan Stanley Global Healthcare Conference

* REG-ZEALAND PHARMA TO PRESENT AT MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE IN NEW YORK ON SEPTEMBER 12, 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Zealand Pharma Q2 operating loss widens to DKK 94.8 mln

* H1 REVENUE OF DKK 88.4 MILLION/USD 13.6 MILLION (DKK 14.7 MILLION/USD 2.2 MILLION IN FIRST HALF OF 2016)

BRIEF-Zealand Pharma partner starts Phase 1 trials for two novel treatments

* PHASE 1 TRIALS FOR TWO NOVEL TREATMENTS OF OBESITY AND/OR DIABETES INITIATED BY ZEALAND PARTNER BOEHRINGER INGELHEIM

Select another date: